Related Experiment Video
Updated: Jun 21, 2026

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone
D L Kendler1, L Bessette, C D Hill
1Prohealth Clinical Research, University of British Columbia, Vancouver, BC, Canada. kendler@ca.inter.net
Unlabelled:
The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment that was administered less frequently, suggesting the acceptability of the 6-month injection for treatment of bone loss.
Introduction:
The PSQ compares patient preference and satisfaction between a 6-month subcutaneous injection and a weekly oral tablet for treatment of bone loss.
Methods:
Postmenopausal women with low bone mass who enrolled in two separate randomized phase 3 double-blind, double-dummy studies received a 6-month subcutaneous denosumab injection (60 mg) plus a weekly oral placebo or a weekly alendronate tablet (70 mg) plus a 6-month subcutaneous placebo injection. After 12 months, patients completed the PSQ to rate their preference, satisfaction, and degree of bother with each regimen.
Results:
Most enrolled patients (1,583 out of 1,693; 93.5%) answered >or=1 item of the PSQ. Significantly more patients preferred and were more satisfied with the 6-month injection versus the weekly tablet (P < 0.001). More patients reported no bother with the 6-month injection (90%) than the weekly tablet (62%).
Conclusion:
Patients preferred, were more satisfied, and less bothered with a 6-month injection regimen for osteoporosis.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
